New Head For EMA's Orphan Drugs Committee
Executive Summary
A key priority for the new chair will involve reinforcing how the European Medicines Agency’s orphan drugs committee interacts and communicates with other scientific committees at the agency and other international partners.
You may also be interested in...
Orphan Drugs Study Compares EMA's Significant Benefit With HTA's Relative Effectiveness Assessments
A first of its kind study is underway to look at how the significant benefit assessment of orphan products by the European Medicines Agency compares with relative effectiveness assessments by health technology assessment bodies.
New Guidance Brings Welcome Clarity on Practical Application of EU Orphan Drugs Law
EU pharmaceutical companies have welcomed new European Commission guidance that provides greater clarity on how several key provisions of the legislation on orphan drugs should be applied in practice.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.